Results 151 to 160 of about 2,648,071 (263)
Sharing digital health data responsibly: Balancing open science with participant privacy. [PDF]
Nebeker C, Samiei S, Kumar S.
europepmc +1 more source
Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee +7 more
wiley +1 more source
Safeguarding Open Science from exploitative practices. [PDF]
Maupin D, Spick M, Geifman N.
europepmc +1 more source
CT10 regulator of kinase (CRK) and CRK‐Like (CRKL) are signaling adaptors driving cell adhesion, motility, differentiation, and proliferation. SH2‐domain containing (SH) proteins are enriched in YXXP motifs which when phosphorylated create preferred binding sites for CRK family SH2 domains.
Phoebe M. Cousens +8 more
wiley +1 more source
Exploring open science in applied ethology: practice and attitudes among researchers. [PDF]
Nawroth C, Gray H, Olsson IAS.
europepmc +1 more source
The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce +11 more
wiley +1 more source
Evidence Synthesis and Open Science: A Tutorial for Systematic Reviews and Beyond in Audiology Research. [PDF]
Stark RK, Gaeta L.
europepmc +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source
Opening the review: perceptions and challenges of Open Science at CSP. [PDF]
Dias de Lima L +3 more
europepmc +1 more source

